Showing results (61-70 of 297) with videos related to
Sort By:
Pageof 30
Therapeutic Advances in Rare Disease|July 22, 2025
Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT studyBrad H Rovin, Radko Komers, Chris Scroggins, et al.Clinical and Experimental Nephrology|February 14, 2019
New strategies and perspectives on managing IgA nephropathyHaresh Selvaskandan, Chee Kay Cheung, Masahiro Muto, et al.Kidney International|March 25, 2019
IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first descriptionHernán Trimarchi, Jonathan Barratt, Renato C Monteiro, et al.Seminars in Immunopathology|September 14, 2007
Immunopathogenesis of IgANJonathan Barratt, Alice C Smith, Karen Molyneux, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 16, 2008
Littoral cell angioma of the spleen mimicking posttransplantation lymphoma in a 63-year-old renal transplant patientAnja Susanne Mühlfeld, Frank Eitner, Alberto Perez-Bouza, et al.Journal of Leukocyte Biology|August 18, 2020
Allosteric targeting of the FFA2 receptor (GPR43) restores responsiveness of desensitized human neutrophilsRobert Frei, Johannes Nordlohne, Ulrike Hüser, et al.Journal of Nephrology|November 20, 2024
Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicineMehmet Kanbay, Lasin Ozbek, Mustafa Guldan, et al.Seminars in Nephrology|September 5, 2018
Aberrant Glycosylation of the IgA1 Molecule in IgA NephropathyJan Novak, Jonathan Barratt, Bruce A Julian, et al.Contributions to Nephrology|May 15, 2007
International IgA nephropathy network clinico-pathological classification of IgA nephropathyJohn Feehally, Jonathan Barratt, Rosanna Coppo, et al.Pharmaceutical Statistics|November 3, 2023
Conditional power and information fraction calculations at an interim analysis for random coefficient modelsSandra A Lewis, Kevin J Carroll, Todd DeVries, et al.Pageof 30